At the 19th Congress of the European Hematology Association (EHA), Professor John Gribben from Bart’s Hospital in London explains why he is excited about promising new treatments for patients with chronic lymphocytic leukaemia (CLL). He discusses the latest on trials in new agents, which are based on understanding the biology of disease. Ibrutinib showed significant benefits compared to standard ofatumumab therapy. Idelalisib, combined with rituximab, showed continued significant benefits in a follow-up study. ABT-199 provided deeper responses in patients and it is therefore hoped to allow a shorter or defined treatment time.
Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network
View more programs featuring
Prof John Gribben